CONTUSUGENE LADENOVEC

also known as Ad5CMV-p53 · Ad-p53 · INGN-201 · Ad5CMV-p53 gene · adenovirus p53 · adeno-p53 · ADVEXIN · Contusugen ladenovec

targets TP53

Developed for: breast cancer · head and neck cancer · lung cancer · squamous cell carcinoma · bladder transitional cell carcinoma · cancer · carcinoma in situ of oropharynx · central nervous system neoplasm
+10 more
· head and neck squamous cell carcinoma · liver cancer · lymphoma · metastatic malignant neoplasm · oral cavity cancer · oral cavity carcinoma in situ · ovarian cancer · ovarian carcinoma · peritoneum cancer · tongue carcinoma
Investigated by: National Cancer Institute (NCI) · Introgen Therapeutics · Eastern Cooperative Oncology Group · MultiVir, Inc. · Aventis Pharmaceuticals · Department of Health and Human Services
+4 more
· M.D. Anderson Cancer Center · SWOG Cancer Research Network · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · University of Texas Southwestern Medical Center

Trials 18 · a red edge is where a trial was stopped

today NCT02842125 · Ph 1/2 NCT03544723 · Ph 2 NCT00410865 · Ph 1 NCT00064103 · Ph 1/2 NCT00017173 · Ph 2 NCT00044993 · Ph 2 NCT00004225 · Ph 1 NCT00004041 · Ph 1 NCT00004038 · Ph 1 NCT00003649 · Ph 1 NCT00003450 · Ph 1 NCT00003588 · Ph 1 NCT00003167 · Ph 1 NCT00003147 · Ph 1 NCT00003257 · Ph 2

199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 19 trials
Phase 1	NCT00410865	Jun 2003 → Mar 2008	oral cavity cancer	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 1	NCT00004225	Jan 2000 → ?	lung cancer	Eastern Cooperative Oncology Group	Completed	No outcome recorded
Phase 1	NCT00004041	Feb 1999 → Jul 2002	central nervous system neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 1	NCT00004038	Jan 1999 → May 2001	breast cancer	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00003649	Nov 1998 → Jun 2007	lung cancer	Eastern Cooperative Oncology Group	Completed	No outcome recorded
Phase 1	NCT00003450	Sep 1998 → Jan 1999	ovarian cancer, peritoneum cancer	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 1	NCT00003588	Sep 1998 → Mar 2002	ovarian carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00003167	May 1998 → Dec 2002	bladder transitional cell carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00003147	Feb 1998 → Jun 2003	liver cancer	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT02842125	Nov 2018 → May 2020	head and neck squamous cell carcinoma, metastatic malignant neoplasm	MultiVir, Inc.	Terminated	No outcome recorded
Phase 1/2	NCT00064103	Jun 2003 → Aug 2007	carcinoma in situ of oropharynx, oral cavity carcinoma in situ, tongue carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 25 trials
Phase 2	NCT03544723	Oct 2018 → Jun 2022	cancer, lymphoma	MultiVir, Inc.	Unknown	No outcome recorded
Phase 2	NCT00017173	Feb 2003 → May 2007	head and neck cancer	SWOG Cancer Research Network	Terminated	No outcome recorded
Phase 2	NCT00044993	Feb 2002 → Aug 2004	breast cancer	Introgen Therapeutics	Completed	No outcome recorded
Phase 2	NCT00003257	Jan 1998 → ?	head and neck cancer	Aventis Pharmaceuticals	Unknown	No outcome recorded
Phase 2	NCT00286247	—	breast cancer	Introgen Therapeutics	Completed	No outcome recorded
Phase 32 trials
Phase 3	NCT00041626	—	squamous cell carcinoma	Introgen Therapeutics	Unknown	No outcome recorded
Phase 3	NCT00041613	—	squamous cell carcinoma	Introgen Therapeutics	Unknown	No outcome recorded

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 20 sources stand behind the page.

Field	Value	Cited text
Known as	CONTUSUGENE LADENOVEC	ChEMBL registry synonym — accepted as the source's own label CHEMBL2108585 ↗
Known as	Ad-p53	“This pilot phase I trial evaluated the safety and maximum-tolerated dose of p53 gene transfer using an adenovirus vector (Ad-p53) delivered via bronchoalveolar lavage (BAL) to...” PMID 18757331 ↗ Sep 2008 5 “Determine the effect of adenovirus p53 (Ad-p53) on chemotherapy-induced apoptosis in lesions in patients with breast cancer.” NCT00004038 ↗ “Patients receive daily intraperitoneal injections of adenovirus p53 (Ad-p53) for 5 days every 3 weeks.” NCT00003588 ↗ “adenovirus p53 gene (Ad-p53)” NCT00004041 ↗ NCT02842125 ↗ NCT03544723 ↗
Known as	Ad5CMV-p53	“Ad5CMV-p53” NCT00064103 ↗ 10 NCT00003588 ↗ NCT00017173 ↗ NCT00004225 ↗ NCT00003649 ↗ NCT00003450 ↗ NCT00064103 ↗ NCT00003257 ↗ NCT00004038 ↗ NCT00044993 ↗ NCT00003147 ↗
Known as	Ad5CMV-p53 gene	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004041 ↗ 1 NCT00003167 ↗
Known as	adeno-p53	“adenovirus p53 construct (adeno-p53)” NCT00003147 ↗
Known as	adenovirus p53	“Determine the effect of adenovirus p53 (Ad-p53) on chemotherapy-induced apoptosis in lesions in patients with breast cancer.” NCT00004038 ↗ 1 “Patients receive daily intraperitoneal injections of adenovirus p53 (Ad-p53) for 5 days every 3 weeks.” NCT00003588 ↗
Known as	ADVEXIN	“ADVEXIN” NCT00064103 ↗
Known as	Contusugen ladenovec	ChEMBL registry synonym — accepted as the source's own label CHEMBL2108585 ↗
Known as	INGN-201	“local administration of INGN 201 (Ad5CMV-p53) in Locally Advanced Breast Cancer (LABC)” NCT00044993 ↗ 5 “INGN-201” NCT00064103 ↗ NCT00410865 ↗ NCT00041613 ↗ NCT00286247 ↗ NCT00041626 ↗
Action	Restore	“Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer.” NCT00017173 ↗
Route	Other	“by percutaneous injection” NCT00003147 ↗
Target	TP53	“Inserting the p53 gene into a person's bladder cancer cells” NCT00003167 ↗